Latest News

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.

According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.

According to data from the 2024 EHA Congress, long-term results of the phase 3 SIERRA trial demonstrated that conditioning and induction with 131I-apamistamab (Iomab-B) was well-tolerated and allowed for access to HCT with curative potential...

Olutasidenib treatment demonstrated efficacy and a consistent safety profile for patients with relapsed/refractory mutant IDH1 acute myeloid leukemia previously treated with venetoclax, according to a subset analysis from a phase 2 study.

Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.

The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...

The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.

According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.

The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.

Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...